var data={"title":"Rimantadine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rimantadine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6893?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">see &quot;Rimantadine: Drug information&quot;</a> and <a href=\"topic.htm?path=rimantadine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rimantadine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50907069\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=12769\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=12769\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216937\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flumadine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055276\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055271\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">see &quot;Rimantadine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pediatric: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza A; prophylaxis:</b> <b>Note:</b> Due to high levels of resistance in circulating influenza strains, rimantadine has not been recommended for prevention in the US over the past several years (CDC 2016); refer to current CDC/ACIP guidelines for updated recommendations. Monotherapy is not recommended. In order to control outbreaks in institutions, if influenza A virus subtyping is unavailable and oseltamivir-resistant viruses are circulating, rimantadine may be used in combination with oseltamivir if zanamivir cannot be used. Therapy should continue for &ge;2 weeks and until ~10 days after illness onset in the last patient (CDC 2016; IDSA [Bradley 2011]; Harper 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 9 years: Oral: 5 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 150 mg/<b>day </b>(CDC 2016; IDSA [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;10 years and Adolescents: Oral: 5 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 200 mg/<b>day </b>(CDC 2016; IDSA [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza A infection; treatment:</b> <b>Note:</b> Due to high levels of resistance in circulating influenza strains, rimantadine has not been recommended for treatment in the US over the past several years (CDC 2016); refer to current CDC/ACIP guidelines for updated recommendations. Optimal duration not established but typical duration of treatment is 5 to 7 days; discontinue as soon as clinically warranted to reduce the emergence of antiviral drug-resistant viruses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 9 years: Oral: 6.6 mg/kg/day in 2 divided doses; maximum daily dose: 150 mg/<b>day</b> (IDSA [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;10 years and Adolescents: Oral: 5 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 200 mg/<b>day </b>(IDSA [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A (CDC/ACIP 2011). Please refer to the current Advisory Committee on Immunization Practices (ACIP) recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza A virus, prophylaxis:</b> Oral: 100 mg twice daily for 7 days after last known exposure. In institutional outbreaks, continue prophylaxis for at least 2 weeks and up to 7 days after the last known case identification. For prophylaxis after inactivated influenza vaccination, continue until immunity after vaccination develops (~2 weeks) (CDC 2016; CDC/ACIP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza A virus, treatment:</b> Oral: 100 mg twice daily for 5 to 7 days. <b>Note:</b> Initiate within 48 hours of symptom onset (CDC/ACIP 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: Dose adjustment not required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: 100 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Nondialyzable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: 100 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216915\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flumadine: 100 mg [contains fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216901\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055279\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May administer with food</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4625353\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055278\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of influenza A viral infection (FDA approved in ages &ge;17 years and adults); prophylaxis of influenza A virus (FDA approved in ages &ge;1 year and adults); <b>Note:</b> Due to high levels of resistance in circulating influenza strains, rimantadine has not been recommended for treatment or prevention in the US over the past several years (CDC 2016); refer to current CDC/ACIP guidelines for updated recommendations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216965\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RiMANTAdine may be confused with amantadine, raNITIdine, Rimactane </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flumadine may be confused with fludarabine, flunisolide, flutamide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216962\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, fatigue, headache, insomnia, lack of concentration, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal gait, agitation, altered sense of smell, ataxia, bronchospasm, cardiac failure, confusion, depression, diarrhea, dysgeusia, dyspnea, euphoria, hallucination, heart block, hyperkinesia, hypertension, lactation, palpitations, pedal edema, seizure, skin rash, syncope, tachycardia, tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216922\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to rimantadine, other adamantanes (eg, amantadine), or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216905\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Influenza A: Appropriate use: Consult current guidelines. Due to increased resistance, the ACIP has recommended that rimantadine and amantadine no longer be used for the treatment or prophylaxis of influenza A in the United States until susceptibility has been re-established (CDC 2011). Rimantadine is not effective in the prevention or treatment of influenza B virus infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Use with caution in patients with a history of seizure disorder; an increase in seizure incidence may occur. Discontinue if seizures occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: The elderly are at higher risk for CNS (eg, dizziness, headache, weakness) and gastrointestinal (eg, nausea/vomiting, abdominal pain) adverse events; dosage adjustment is recommended in patients &gt;65 years of age. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Resistance: May develop during treatment; viruses exhibit cross-resistance between amantadine and rimantadine. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300002\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216910\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12769&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216911\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216925\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Neuraminidase inhibitors are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Appropriate antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (CDC 60[1] 2011; CDC March 13, 2014; CDC January 2015).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to refer women exposed to influenza vaccine, or who have taken an antiviral medication during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at 1-877-311-8972. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216904\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exerts its inhibitory effect on three antigenic subtypes of influenza A virus (H1N1, H2N2, H3N2) early in the viral replicative cycle, possibly inhibiting the uncoating process; it has no activity against influenza B virus and is two- to eightfold more active than amantadine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216921\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Antiviral activity: No data exist establishing a correlation between plasma concentration and antiviral effect </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Children: 289 L (Anderson 1987); Adults: 727 to 768 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein Binding: ~40%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via hydroxylation and glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 5 to 8 years: 24.8 &plusmn; 9.4 hours (Anderson 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 25.4 hours (range: 13 to 65 hours); Elderly (71 to 79 years of age): 32 hours (range: 20 to 65 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;25% as unchanged drug) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10297270\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">Rimantadine 10 mg/mL Suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">To prepare suspension, 10 mL of Ora-Sweet&reg; will be required for every 100 mg tablet of rimantadine. (Do not prepare more than a 14-day supply). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Calculate the total dose needed (daily dose x number of days = mg of rimantadine needed) and round the final mg of rimantadine needed up to the next 100 mg (eg, 750 mg would be 800 mg, or eight 100 mg tablets).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Calculate the total volume of Ora-Sweet&reg; by taking the rounded mg of rimantadine and dividing by 10 mg/mL (eg, 800 mg divided by 10 mg/mL = 80 mL).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Grind required number of tablets in mortar and triturate to a fine powder. Slowly add <sup>1</sup>/<sub>3</sub> of the total volume of Ora-Sweet&reg; to the mortar and triturate until a uniform suspension is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Transfer to an amber glass or PET plastic bottle. Slowly add another <sup>1</sup>/<sub>3</sub> of the total volume of Ora-Sweet&reg; to the mortar, rinsing the mortar, then transferring the contents into the bottle. Repeat using the final 1/3 of Ora-Sweet&reg;. Add additional vehicle to bottle, if needed, to achieve the total calculated volume.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Shake well to ensure homogeneous suspension. Some inert ingredients in the tablet may be insoluble.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Label: Shake gently prior to each use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Suspension is stable for 14 days when stored at room temperature (25&deg;C/77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216924\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Flumadine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $262.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (RiMANTAdine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $324.87</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216927\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gabirol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Jin Di Na (CN);</li>\n      <li>Oclovir (AR);</li>\n      <li>Remantadin (BG);</li>\n      <li>Roflual (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Recomm Rep</i>, 2011, 60(1):1-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/21248682/pubmed\" target=\"_blank\" id=\"21248682\">21248682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Antiviral Drugs: Information for Health Care Professionals. 2017. Available at <a href=\"https://www.cdc.gov/flu/professionals/antivirals/antiviral-dosage.htm\">https://www.cdc.gov/flu/professionals/antivirals/antiviral-dosage.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. March 13, 2014. Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. March 13, 2014. Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harper SA, Bradley JS, Englund JA, et al, &quot;Seasonal Influenza in Adults and Children - Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2009, 48(8):1003-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/19281331/pubmed\" target=\"_blank\" id=\"19281331\">19281331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Jamieson DJ, Rasmussen SA. 2009 pandemic influenza A (H1N1) virus infection in postpartum women in California. <i>Am J Obstet Gyneco</i>l. 2011;204(2):144.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/21074132 /pubmed\" target=\"_blank\" id=\"21074132 \">21074132 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12769 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50907069\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216937\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055276\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055271\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216915\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F216901\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055279\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F4625353\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055278\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F216965\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216962\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216922\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216905\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300002\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216910\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F216911\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216925\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216904\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F216921\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10297270\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F216924\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F216927\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12769|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">Rimantadine: Drug information</a></li><li><a href=\"topic.htm?path=rimantadine-patient-drug-information\" class=\"drug drug_patient\">Rimantadine: Patient drug information</a></li></ul></div></div>","javascript":null}